



Biotech Daily

Thursday September 25, 2025

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH UP: 4D MEDICAL UP 14%; NOVA EYE DOWN 6%**
- * **ARTRYA: DEMAND FORCES EARLY SHARE PLAN CLOSURE**
- * **LUMOS: UK STUDY 'FEBRIDX REDUCES ANTIMICROBIAL RESISTANCE'**
- * **MONASH UNI 'VIRUS COCKTAIL KILLS SUPERBUGS, IN MICE'**
- * **RECCE STARTS PHASE III R327G DIABETIC FOOT INFECTION TRIAL**
- * **AEGROS BIOPHARMA IN ADMINISTRATION**
- * **ANTEOTECH, BLACK DIAMOND WORK ON SILICON-LITHIUM BATTERY**
- * **CURVEBEAM REQUESTS 'PLACEMENT' TRADING HALT**
- * **INVEX TAKES 'ACQUISITION, ASX PRICE QUERY' HALT TO SUSPENSION**
- * **REGAL TAKES 7.8% OF ARTRYA**
- * **ANACACIA REDUCES TO 6.8% OF COGSTATE**

MARKET REPORT

The Australian stock market was up 0.1 percent on Thursday September 25, 2025, with the ASX200 up 8.5 points to 8,773.0 points. Eighteen of the Biotech Daily Top 40 companies were up, 12 fell, nine traded unchanged and one was untraded.

4D Medical was the best, up 21.5 cents or 14.0 percent to \$1.75, with 10.7 million shares traded. Atomo and Botanix climbed more than seven percent; Clarity and Resonance rose more than five percent; Dimerix, Imricor and Starpharma improved four percent or more; Compumedics was up 3.5 percent; Immutep and SDI rose two percent or more; Cyclopharm, Medical Developments, Mesoblast, Orthocell and Polynovo were up more than one percent; with CSL, EBR, Neuren and Pro Medicus up by less than one percent.

Nova Eye led the falls, down one cent or 6.1 percent to 15.5 cents, with 564,708 shares traded. Impedimed fell 5.4 percent; Genetic Signatures and Paradigm lost more than three percent; Clinuvel, Medadvisor, Prescient and Resmed shed two percent or more; Cochlear and Imugene were down more than one percent; with Avita, Emvision, Nanosonics and Telix down by less than one percent.

[ARTRYA](#)

Artrya says its up-to \$5 million share plan has received applications exceeding \$5 million “following strong early demand” and will close early to lessen the scale back.

Earlier this month, Artrya said it had commitments for a \$75 million placement at \$2.05 a share, with an up-to \$5 million share plan to follow, closing on October 3, 2025, with the company reserving the right to accept oversubscriptions (BD: Sep 9, 2025).

Today, the company said the revised closing date would be Friday, September 26, 2025, with applications received after that date not accepted and application monies to be returned to the applicant in full.

Artrya said it would “scale back of applications received prior to the revised closing date and may also accept applications that result in the [plan] raising more than \$5 million”.

Artrya was up 10 cents or 4.55 percent to \$2.30 with 642,080 shares traded.

[LUMOS DIAGNOSTICS](#)

Lumos says that 85 percent of 326 people using its Febridx test in England found it ‘useful’ with the authors saying the test reduced antimicrobial resistance.

Lumos said the data was in a poster, titled ‘Evaluating a rapid viral vs bacterial point of care test (CRP + MxA) to support diagnosis and appropriate antibiotic prescribing in Calderdale, West Yorkshire [Integrated Care Board]’ was presented at the Primary Care Respiratory Society meeting in Telford, England.

The company said that the poster reported on about two years use of its Febridx finger-prick blood test to differentiate bacterial from viral respiratory infections, at general practitioner practices, urgent care and acute respiratory infection (ARI) hubs.

Lumos said the study of the Febridx test showed “a measurable reduction in antibiotic prescribing, by helping clinicians distinguish viral versus bacterial infections; improved patient experience, by reducing re-consultations, indicating greater confidence and resolution of illness without repeat visits; significant cost savings to the health system, by preventing unnecessary antibiotic prescriptions, reducing repeat [general practitioner] visits, and keeping patients out of the hospital; healthcare system benefits [with] 36 percent of patients [reporting] they would have otherwise attended [hospital accident and emergency] if the [acute respiratory infection, or ARI] hub was not available”.

The poster said a retrospective patient survey had 1,186 responses from 7,102 ARI hub appointments eligible for a test, a 16.7 percent response rate.

The poster reported this proportion was higher in the patient cohort who had a test (40%), with a total of 326 of 1,186 patients (27.5%) patients surveyed received a test, of which 279 patients (85.6%) found the test useful.

The study concluded: “A rapid, portable, finger-prick diagnostic test in primary care was well-received by patients, provided reassurance and guided appropriate antibiotic use.”

“By empowering frontline care, it aligns with the UK Government’s shift from ‘hospital to community’ and ‘sickness to prevention’ offering a practical tool to fight [antimicrobial resistance],” the report concluded.

“Distinguishing viral from bacterial respiratory infections is challenging and misdiagnosis can lead to unjustified prescription of antibiotics - a major driver of antimicrobial resistance (AMR),” the poster said.

“Our previous evaluation showed that a rapid ... point-of-care test changed prescribing decisions in 45 percent of cases and reduced antibiotic use, and our latest study showed that incorporating the test within primary care appointments is well accepted by patients,” the poster concluded.

Lumos was unchanged at 15.5 cents with 7.2 million shares traded.

MONASH UNIVERSITY

Monash University says it has developed a phage therapy using bacterial viruses, or bacteriophages, to combat anti-microbial resistant bacteria, in mice.

The University said Entelli-02 was a five-phage 'cocktail' targeting *Enterobacter cloacae* complex (ECC), a bacteria group responsible for severe, often difficult-to-treat infections. The study, titled 'Rational design of a hospital specific phage cocktail to treat *Enterobacter cloacae* Complex infections', was published in *Nature Microbiology* with the full article available at: <https://www.nature.com/articles/s41564-025-02130-4>.

Monash University said the study, with the Alfred Hospital, and led by Prof Jeremy Barr and Prof Anton Peleg, was "a new approach for precision medicine in hospitals battling antimicrobial resistance (AMR)".

"This is the first time we've designed and developed a clinical-ready phage therapy product tailored to an AMR bacterial pathogen at a local hospital," Prof Barr said.

"Entelli-02 is not just a scientific achievement, it's a clinical tool built for frontline use against deadly, drug-resistant, bacterial pathogens," Prof Barr said.

Monash University said that *Enterobacter* infections were "notoriously difficult to treat" and were linked to more than 200,000 deaths in 2019, having "emerged in hospitals ... [and had] the capacity to develop resistance to many of the last-line antibiotics".

Lead author Dr Dinesh Subedi said Entelli-02, had five phages that killed "a broad range of *Enterobacter* isolates and reduce bacterial loads in infected mice by over 99 percent".

Monash University said that Entelli-02 was available for compassionate use with potential clinical trials using phage products.

RECCE PHARMACEUTICALS

Recce says dosing has begun in its up-to 310 patient, phase III, randomized, controlled trial of R327 topical gel for diabetic foot infections at five sites in Indonesia.

Recce said it expected a read-out of results by April 2026, and if "a positive result [was] confirmed by the independent data management committee, a submission for accelerated approval [would] be pursued with a potential commercial launch in 2026".

The company said that patients would receive either R327 topical gel (R327G) or placebo, with the trial's primary objective "to assess the clinical response of the [diabetic foot infections] according to the Lipsky scale, which was recognized by the US Food and Drug Administration.

Recce said the secondary endpoints included a total wound score and safety of R327G including clinical observations and adverse events.

The company said it expected "to meet a highly statistically significant positive endpoint after dosing approximately 155 patients".

Recce said that the Indonesian Drug and Food Regulatory Authority approved protocol had "a built-in interim analysis as well as expedited regulatory review status", with an independent data management committee to complete this analysis and make recommendations by April 2026.

Recce chief executive officer James Graham said that "with R327G positioned as the first potential treatment for [diabetic foot infections], we see ourselves well positioned to meet the infectious disease challenges among the global rise in diabetes".

Recce said that more than 20.9 million adults in Indonesia were living with diabetes, about 11.3 percent of the adult population, ranking it fifth in the world for diabetes prevalence and among the highest rates in South East Asia.

Recce was up 2.5 cents or 6.4 percent to 41.5 cents.

[AEGROS BIOPHARMA PTY LTD](#)

RSM Australia says that partners Mitchell Herrett, and Brett Lord have been appointed administrators of Aegros Biopharma Pty Ltd and called a creditors' meeting.

Mr Lord told Biotech Daily that Aegros Biopharma Pty Ltd, was a subsidiary of Aegros Ltd. "Aegros Ltd is unaffected by the appointment of the administrators to the subsidiary," Mr Lord said.

RSM Australia said the first creditors meeting would be held at RSM, Level 3, 488 Queen Street Brisbane on October 1, 2025 at 11am (AEST).

In July, Aegros said that founders John Manusu and Prof Hari Nair has stepped down to non-executive directors, with property developer Ray Nolan appointed chair and Damian Thornton appointed chief executive officer, with James Clyne as chief financial officer and company secretary, and non-executive directors including Anne Duggan, David Burns, John Clarke, Max Grundeman and Janet Bowen (BD: Jul 4, 2025).

The Aegros website said Mr Thornton joined Aegros in January 2022, and "spear-headed the design and establishment of its technologically advanced 125,000 litre Hyperimmune Haemafrac facility in Macquarie Park, [New South Wales]".

An Aegros spokesman told Biotech Daily at that time that Aegros raised \$37 million at \$1.00 a share, with Mr Nolan providing \$20 million and clients of STK Markets providing the \$17 million balance, while Daniel Phillips' Fresh Start Australia and Mark Garkawe's L39 Capital remained shareholders.

Last year, then Aegros chief executive officer Mr Manusu said that the plasma fractionator hoped to raise \$100 million at \$18.00 a share "in the near term" with the funds to complete the \$65 million Sydney manufacturing plant for its hyperimmune products, including its first intended product for Covid-19 (BD: Apr 2, 2024).

In 2022, the Queensland Government said it had invested in Aegros' \$352 million facility in Brisbane for blood fractionation and plasma therapeutic use, but did not quantify the amount (BD: Nov 25, 2022).

Aegros is a public unlisted company.

[ANTEOTECH](#)

Anteotech says it has a joint development and sales agreement with the Austin, Texas-based Black Diamond Structures LLC for a combined battery product for the US.

In July, Anteotech said that the product would combine its 'cross linker' Anteo X battery with Black Diamond's single and multi-walled Molecular Rebar carbon nano-tube dispersion technology into a high silicon lithium-ion battery for "battery manufacturers incorporating greater than 10 percent silicon by weight active material in their anodes" (BD: Jul 21, 2025).

Anteotech managing-director Merrill Gray said the agreement strengthened "the long-standing relationship and [established] a basis for accelerated entry by Anteotech into the critical US battery market.

Anteotech was unchanged at 2.4 cents with 10.85 million shares traded.

[CURVEBEAM A.I.](#)

Curvebeam has requested a trading halt pending "an announcement in relation to a proposed equity capital raising by way of [an] institutional placement".

Trading will resume on September 29, 2025, or on an earlier announcement.

Curvebeam last traded at 11 cents.

INVEX

Invex has requested a suspension to follow the halt requested on September 23, pending “a material acquisition announcement and responses to an ASX price query”.
Invex last traded at 16 cents.

ARTRYA

Sydney’s Regal Funds Management says it has increased its substantial shareholding in Artrya from 9,670,354 shares (6.58%) to 11,536,379 shares (7.80%).
Regal Funds said it bought shares between September 16 and 22, 2025, with the single largest purchase on September 18 of 506,832 shares for \$1,104,894 or \$2.18 a share.

COGSTATE

Sydney’s Anacacia Pty Ltd says it has reduced its substantial shareholding in Cogstate from 14,023,266 shares (8.2%) to 11,638,439 shares (6.8%).
Anacacia portfolio manager Tom Granger said that between September 3, 2024 and November 22, 2024 the company bought 775,000 shares for \$648,797, or 83.7 cents a share; and between February 20, 2025 and September 23, 2025 sold 3,159,827 shares for \$5,853,610 or \$1.8525 a share.
Cogstate was up three cents or 1.4 percent to \$2.17.